ADMA Biologics (NASDAQ:ADMA) Reaches New 52-Week High at $6.80

ADMA Biologics, Inc. (NASDAQ:ADMA - Get Free Report) shares reached a new 52-week high on Friday . The company traded as high as $6.80 and last traded at $6.70, with a volume of 708040 shares. The stock had previously closed at $6.74.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on the stock. Mizuho boosted their price target on shares of ADMA Biologics from $9.00 to $10.00 and gave the stock a "buy" rating in a research note on Friday, March 1st. Cantor Fitzgerald increased their price objective on shares of ADMA Biologics from $6.50 to $8.00 and gave the stock an "overweight" rating in a research report on Thursday, February 29th. Finally, HC Wainwright reissued a "buy" rating and set a $7.50 price objective (up previously from $6.00) on shares of ADMA Biologics in a research report on Tuesday, March 26th. One equities research analyst has rated the stock with a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Buy" and an average price target of $7.88.

ADMA Biologics Trading Up 1.0 %

The company has a debt-to-equity ratio of 1.04, a quick ratio of 1.69 and a current ratio of 5.16. The stock has a market capitalization of $1.55 billion, a P/E ratio of -51.54 and a beta of 0.43. The firm's fifty day simple moving average is $6.18 and its 200 day simple moving average is $4.96.

ADMA Biologics (NASDAQ:ADMA - Get Free Report) last posted its quarterly earnings results on Wednesday, February 28th. The biotechnology company reported $0.04 earnings per share for the quarter, beating analysts' consensus estimates of $0.02 by $0.02. ADMA Biologics had a negative net margin of 10.94% and a positive return on equity of 0.49%. The company had revenue of $73.90 million for the quarter, compared to the consensus estimate of $73.50 million. As a group, equities research analysts forecast that ADMA Biologics, Inc. will post 0.3 EPS for the current fiscal year.

Insider Buying and Selling

In related news, Director Steve Elms sold 407,000 shares of the business's stock in a transaction dated Wednesday, March 13th. The shares were sold at an average price of $6.21, for a total value of $2,527,470.00. Following the transaction, the director now directly owns 3,208,671 shares of the company's stock, valued at approximately $19,925,846.91. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. In the last ninety days, insiders have sold 639,895 shares of company stock valued at $3,927,169. 6.00% of the stock is owned by insiders.

Institutional Investors Weigh In On ADMA Biologics

Several hedge funds and other institutional investors have recently modified their holdings of ADMA. GSA Capital Partners LLP increased its position in shares of ADMA Biologics by 87.7% in the third quarter. GSA Capital Partners LLP now owns 242,284 shares of the biotechnology company's stock worth $867,000 after purchasing an additional 113,184 shares during the last quarter. Qube Research & Technologies Ltd raised its position in ADMA Biologics by 22.9% in the 3rd quarter. Qube Research & Technologies Ltd now owns 1,204,648 shares of the biotechnology company's stock worth $4,313,000 after buying an additional 224,696 shares during the last quarter. American Century Companies Inc. raised its position in ADMA Biologics by 20.8% in the 3rd quarter. American Century Companies Inc. now owns 4,892,123 shares of the biotechnology company's stock worth $17,514,000 after buying an additional 840,761 shares during the last quarter. Aigen Investment Management LP purchased a new stake in shares of ADMA Biologics during the 3rd quarter valued at about $140,000. Finally, SG Americas Securities LLC increased its position in shares of ADMA Biologics by 417.3% during the 4th quarter. SG Americas Securities LLC now owns 93,236 shares of the biotechnology company's stock valued at $421,000 after purchasing an additional 75,213 shares during the last quarter. 75.68% of the stock is currently owned by institutional investors.

ADMA Biologics Company Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.